Integra LifeSciences Holdings Corporation Investigation - IART

Company: Integra LifeSciences Holdings Corporation (NASDAQ: IART)

Learn more about the Integra LifeSciences Holdings Corporation Investigation

Required Field

$1 - $1,000
$1001 - $10,000
$10,001 - $25,000
$25,001 - $50,000
$50,001 - $100,000
$100,001 - $250,000
$250,001 - $500,000
$500,000+

Full Name

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

* By checking this box, you agree to receive text messages from us, at the cell number you provided above, regarding new cases and case updates. Reply STOP to cancel. Msg frequency varies. Msg and data rates may apply. View Terms & Privacy

Please Upload related files below

Add Transactions

Purchases

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Purchases

Sales

1.

Common Stock
Preferred Stock
Bonds
Calls
Puts

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Integra LifeSciences Holdings Corporation Investigation Details

Integra LifeSciences Holdings Corporation were falling nearly 20% midday on October 2, 2026, after the company lowered its full-year 2026 guidance and reported preliminary third-quarter revenue below analyst estimates. The company attributed the guidance cut and revenue shortfall to a July flood at its Cincinnati manufacturing facility, which damaged production assets and disrupted product supplies. The disruption is expected to further reduce fourth-quarter revenue by approximately $15 million to $20 million, with full manufacturing operations at the facility not expected to resume until the second quarter of 2027. During the previous earnings call on July 29, 2026, Chief Financial Officer Lea Daniels Knight indicated the company did "not expect the event to have a material impact on our revenue or EPS guidance for 2026."

Get Started